On February 23 (Beijing Time), C Ray Therapeutics officially achieved Full Accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), the globally recognized gold standard in laboratory animal care and research ethics.

This milestone reflects C Ray's long-standing commitment to maintaining the highest international standards in laboratory animal welfare, research integrity, and quality management systems.

AAALAC accreditation is awarded through a rigorous and comprehensive evaluation process, including detailed documentation review and on-site assessments. Full Accreditation is granted only to organizations that demonstrate exceptional animal care practices and full compliance with globally recognized guidelines, including the Guide for the Care and Use of Laboratory Animals.

·A Strategic Enabler for Global Partners

“AAALAC Full Accreditation is more than a compliance milestone—it is a strategic enabler for our clients,” said Haitao Qiao, General Manager of C Ray Therapeutics. “Biotech companies developing novel radiopharmaceuticals can now conduct preclinical research in China with confidence that their data will align with Western regulatory expectations, while leveraging our integrated IIT framework to accelerate first-in-human timelines to 6–9 months, compared to traditional development pathways.”

The accreditation covers C Ray's 28,000-square-meter integrated facility, which combines AAALAC-accredited preclinical research capabilities with cGMP manufacturing operations under China's Class A Radiation Safety License—the highest regulatory tier. The platform supports more than 30 radioisotopes, including complex alpha emitters such as Actinium-225.

·Integrated CRDMO Platform with Proven Delivery

To date, C Ray has successfully delivered more than 70 CRDMO projects, including 50 preclinical and molecular imaging CRO programs and 24 CDMO projects. The company has supported five programs through IND and IND-enabling stages, facilitated 16 investigator-initiated trials (IITs), and enabled three clinical supply programs, two of which have advanced to Phase III clinical studies.

With over $187 million raised to date, C Ray continues to invest in infrastructure, isotope supply chain partnerships, and regulatory expertise to strengthen its role as a global CRDMO partner in radiopharmaceutical innovation.

About AAALAC International

AAALAC International is a private, nonprofit organization promoting humane treatment of animals in science through voluntary accreditation. Full Accreditation is awarded only after rigorous on-site evaluation and verification of compliance with international guidelines including the Guide for the Care and Use of Laboratory Animals.

About C Ray Therapeutics

C Ray Therapeutics is a global CRDMO providing end-to-end radiopharmaceutical development services—from target validation and preclinical evaluation to IND enabling, clinical supply, and commercial-scale cGMP manufacturing. Operating from its 28,000-square-meter Chengdu facility with China's Class A Radiation Safety License, C Ray supports 30+ radioisotopes and has delivered 70+ projects spanning diagnostic and therapeutic programs. The company's IIT-powered clinical pathway enables first-in-human data in 6-9 months, accelerating timelines for novel RLT development. For more information, visit C-Ray Therapeutics: | LinkedIn